CRISPR Therapeutics (CRSP) and Sirius Therapeutics have entered a collaboration to develop small interfering RNA-based treatments, starting with SRSD107, a Factor XI-targeting therapy for thromboembolic conditions, the companies said late Monday.
Under the agreement, CRISPR will provide $25 million in cash and $70 million in equity to Sirius upfront. The companies will jointly develop SRSD107 under a 50-50 cost and profit-sharing model, with CRISPR leading US commercialization and Sirius overseeing Greater China.
CRISPR also holds exclusive rights to license up to two additional siRNA programs, according to a joint statement.
SRSD107 is a long-acting siRNA that selectively inhibits Factor XI, a driver of pathological clot formation, with limited effect on normal clotting. Phase 1 trials showed the therapy was safe, well-tolerated, and delivered sustained reductions in FXI levels for up to six months after a single dose, suggesting potential as a twice-yearly treatment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.